Second-tier natural antidepressants: Review and critique

Iovieno, Nadia; Dalton, Elizabeth D.; Fava, Maurizio; Mischoulon, David

doi:10.1016/j.jad.2010.06.010

Cited by 57 publications

(31 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It, too, has only been studied in the short term (4-8 weeks). 102 One RCT of R. rosea monotherapy and sertraline in mild to moderate MDD found that neither condition was significantly different from placebo. 103 R. rosea has mild and infrequent side effects, including nervousness, dizziness, allergy, irritability, insomnia, fatigue, and unpleasant sensations.…”

Section: What Other Natural Health Products Have Been Evaluated In Thmentioning

confidence: 99%

“…103 R. rosea has mild and infrequent side effects, including nervousness, dizziness, allergy, irritability, insomnia, fatigue, and unpleasant sensations. 102,103 Interactions with concomitant medications, such as theophylline and warfarin, have been reported. 104 In summary, for mild to moderate MDD, acetyl-L-carnitine (Level 2 Evidence) is recommended as a third-line monotherapy and C. sativus as third-line monotherapy or adjunctive treatment (Level 2 Evidence) ( Table 3).…”

Section: What Other Natural Health Products Have Been Evaluated In Thmentioning

confidence: 99%

See 1 more Smart Citation

Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine Treatments

Ravindran¹,

Balneaves²,

Faulkner³

et al. 2018

FOC

127

View full text Add to dashboard Cite

Methods: Using the question-answer format, we conducted a systematic literature search focusing on systematic reviews and meta-analyses. Evidence was graded using CANMAT-defined criteria for level of evidence. Recommendations for lines of treatment were based on the quality of evidence and clinical expert consensus. ''Complementary and Alternative Medicine Treatments'' is the fifth of six sections of the 2016 guidelines. Results: Evidence-informed responses were developed for 12 questions for 2 broad categories of complementary and alternative medicine (CAM) interventions: 1) physical and meditative treatments (light therapy, sleep deprivation, exercise, yoga, and acupuncture) and 2) natural health products (St. John's wort, omega-3 fatty acids; S-adenosyl-L-methionine [SAM-e], dehydroepiandrosterone, folate, Crocus sativus, and others). Recommendations were based on available data on efficacy, tolerability, and safety. Conclusions: For MDD of mild to moderate severity, exercise, light therapy, St. John's wort, omega-3 fatty acids, SAM-e, and yoga are recommended as first-or second-line treatments. Adjunctive exercise and adjunctive St. John's wort are second-line recommendations for moderate to severe MDD. Other physical treatments and natural health products have less evidence

show abstract

Section: What Other Natural Health Products Have Been Evaluated In Thmentioning

confidence: 99%

Section: What Other Natural Health Products Have Been Evaluated In Thmentioning

confidence: 99%

Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine Treatments

Ravindran¹,

Balneaves²,

Faulkner³

et al. 2018

FOC

127

View full text Add to dashboard Cite

show abstract

“…Nevertheless, most 5-HTP antidepressant reports are positive [45]. Scholarly reviews conclude 5-HTP has shown promise as an antidepressant, and that more and better trials are warranted [45, 62]. Consistent with its pharmacology, 5-HTP antidepressant effect appears to be more consistent when adjunctive to another 5-HT Ext -elevating antidepressant [45].…”

Section: -Htp Has Shown Promising Antidepressant Effects But Poor Pmentioning

confidence: 99%

Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale

Jacobsen

Krystal

Krishnan

et al. 2016

Trends in Pharmacological Sciences

103

View full text Add to dashboard Cite

Serotonin transporter (SERT) inhibitors treat depression by elevating brain extracellular 5-hydroxytryptamine (5-HTExt). However, only one-third of patients respond adequately. Treatment-resistant depression (TRD) is a major unmet need. Interestingly, elevating 5-HTExt beyond what is achieved by a SERT inhibitor appears to treat TRD. Adjunctive administration of 5-hydroxytryptophan (5-HTP) safely elevates 5-HTExt beyond the SERT inhibitor effect in humans; but, 5-HTP cannot be a clinically viable drug because of its poor pharmacokinetics. A slow-release (SR) delivery mode would be predicted to overcome the pharmacokinetic limitations of 5-HTP, substantially enhance the pharmacological action, and transform 5-HTP into a clinically viable drug. Animal studies bear out this prediction. Thus, adjunct 5-HTP SR could be an important new treatment for TRD. Here we review the clinical and preclinical evidence.

show abstract

“…Based on secondary sources and animal research, rhodiola may be used in combination with conventional antidepressants. 26,50 Preliminary research suggests that rhodiola, specifically the SHR-5 standardized extract, may be beneficial for patients with mild-to-moderate depression and may reduce insomnia, emotional instability, and level of somatization associated with depression. 26,41 Further research is needed before conclusions may be drawn.…”

Section: Depressionmentioning

confidence: 99%

Rhodiola (Rhodiola spp.): An Evidence-Based Systematic Review by the Natural Standard Research Collaboration

UlbrichtCatherine

ChaoWendy²,

Tanguay-ColucciShaina³

et al. 2011

Alternative and Complementary Therapies

View full text Add to dashboard Cite

Second-tier natural antidepressants: Review and critique

Cited by 57 publications

References 92 publications

Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine Treatments

Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine Treatments

Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale

Rhodiola (Rhodiola spp.): An Evidence-Based Systematic Review by the Natural Standard Research Collaboration

Contact Info

Product

Resources

About